ClinicalTrials.gg
TerminatedNCT00649584Updated Dec 18, 2014

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

A Phase 1 interventional study of SGN-35 and gemcitabine in Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Terminated at 5 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
49th of 80
44 · median 52
Started
2008
the only one that year
Phase 1
12 of 80
none open now
Registered
2nd of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 49th largest by enrollment, is the only one that started in 2008, is one of 12 in phase 1, and was the 2nd registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.

03

Conditions studied

  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin

Keywords

  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • monomethyl auristatin E
  • Combined Modality Therapy
  • Drug Therapy
  • Immunotherapy
  • Lymphoma, Non-Hodgkin
  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Hematologic Diseases
  • Lymphoma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed CD30-positive hematologic .
  • Patients with HL must have failed systemic chemotherapy.
  • Patients with other CD30-positive malignancies (including ALCL) must be beyond first remission or to front line chemotherapy.
  • Patients must have of at least 1.5 cm as documented by radiographic technique.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible).
  • History of stem cell transplant.
  • Patients who have had previous treatment with any anti-CD30 antibody.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    1

    SGN-35 alone or in combination with gemcitabine

    Drug: SGN-35 · Drug: gemcitabine

Interventions

  • DrugSGN-35

    IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles

    Also known as: brentuximab vedotin

  • IV; 1000 mg/m2 weekly 3 out of 4 weeks

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and laboratory abnormalities

    Time frame: 1 month after last dose

Secondary outcomes

  1. PK profile

    Time frame: 2 months after last dose

  2. Immunogenicity (anti-SGN-35 antibodies)

    Time frame: 1 month after last dose

  3. Anti-tumor activity

    Time frame: 1 month after last dose

07

Study locations

5 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4003, United States
08

References and documents

Publications

  • Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012 Jan 1;18(1):248-55. doi: 10.1158/1078-0432.CCR-11-1425. Epub 2011 Nov 11. PubMed 22080439 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Apr 1, 2008
Start
Mar 2008
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00649584
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Apr 1, 2008
Start date
Mar 2008
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Dec 18, 2014

Study contacts

Dana Kennedy, PharmD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion